search
Back to results

NTX-001 to Repair Peripheral Nerve Transection(s)

Primary Purpose

Peripheral Nerve Injury Upper Limb

Status
Available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
NTX-001
Sponsored by
Neuraptive Therapeutics Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Peripheral Nerve Injury Upper Limb

Eligibility Criteria

16 Years - 80 Years (Child, Adult, Older Adult)All Sexes

Inclusion:

  • The subject is between 16 and 80 years of age.
  • The subject has clinical evidence of an acute peripheral nerve transection from conditions or interventions that have or may result in motor or sensory impairment amendable to surgical repair.

Exclusion:

  • Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
  • Subjects on chronic corticosteroid therapy within 14 days of repair.
  • The subject is pregnant and/or is breastfeeding.
  • The subject is currently enrolled in another investigational study or has participated in an investigational study within 30 days prior to screening.

Sites / Locations

  • Orlando Health Orthopedic Institute

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
July 21, 2022
Last Updated
October 17, 2023
Sponsor
Neuraptive Therapeutics Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05565846
Brief Title
NTX-001 to Repair Peripheral Nerve Transection(s)
Official Title
An Open-Label Study Using NTX-001 to Repair Peripheral Nerve Transection(s)
Study Type
Expanded Access

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neuraptive Therapeutics Inc.

4. Oversight

5. Study Description

Brief Summary
The proposed use of NTX-001 for transections of peripheral nerves in the upper extremity for subjects that don't qualify for study NTx20201.
Detailed Description
The proposed procedure would employ NTX-001 as a free functional muscle transfer to the upper extremity. This procedure is meant to restore the function of one or two joints in the upper extremity by bringing the gracilis muscle from the leg with its associated obturator nerve and its vascular pedicle. Most commonly, and in this case, as well, elbow flexion is the main function that is targeted for improvement. This is for a brachial plexus injury, and therefore we would be using an extraplexal nerve as a donor nerve to reinnervate the gracilis muscle. Most commonly, this is the spinal accessory nerve. The only proposed direct tension-free coaptation that would be subject to NTX-001 is the spinal accessory nerve to the obturator nerve. The benefit of this would be immediate reinnervation of the gracilis in the arm without a period of muscle atrophy that traditionally occurs with this operation. Usually, the first signs of any muscle contraction occur around 6 months when the patient tries to flex their elbow. With NTX-001, this may be significantly expedited with early return of function and result in greater muscle strength due to the prevention of muscle atrophy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Nerve Injury Upper Limb

7. Study Design

8. Arms, Groups, and Interventions

Intervention Type
Combination Product
Intervention Name(s)
NTX-001
Intervention Description
One-time use surgical product of three solutions and a device

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
80 Years
Eligibility Criteria
Inclusion: The subject is between 16 and 80 years of age. The subject has clinical evidence of an acute peripheral nerve transection from conditions or interventions that have or may result in motor or sensory impairment amendable to surgical repair. Exclusion: Subjects whose nerve repair will occur greater than 48 hours after nerve transection. Subjects on chronic corticosteroid therapy within 14 days of repair. The subject is pregnant and/or is breastfeeding. The subject is currently enrolled in another investigational study or has participated in an investigational study within 30 days prior to screening.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Seth Schulman, MD
Phone
617-416-4520
Email
seth.schulman@neuraptive.com
Facility Information:
Facility Name
Orlando Health Orthopedic Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Available
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karan A Desai, MD
Phone
321-843-5851
Email
Karan.Desai@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
David J Krol, CRC
Phone
321-843-5687
Email
David.Krol@orlandohealth.com

12. IPD Sharing Statement

Learn more about this trial

NTX-001 to Repair Peripheral Nerve Transection(s)

We'll reach out to this number within 24 hrs